Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
A

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin Is Too Much and the Frontline Brentuximab Vedotin Options

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Alison Moskowitz
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Alison Moskowitz
0 views
October 17, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Meet The Professor Sessions
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Feat. M. Mauro
18:04
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Biomarkers To Predict Treatment Free Remission in CML – Can We Predi…

Feat. T. Hughes
19:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Management of Advanced Phase CML: Treatment Options for Accelerated,…

Feat. E. Jabbour
14:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Where do Immunotherapies Fit in the Treatment Landscape of ALL?

Feat. P. Kebriaei
14:33
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How To Cure The Very High Risk Childhood ALL? Dasatinib vs. Imatinib…

Feat. C. Pui
15:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Future of Frontline ALL in Adults: Complex Biological Work up an…

Feat. N. Boissel
14:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Harnessing the Immune System for Treating AML: Targeting CD33 and IL…

Feat. F. Ravandi
15:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

IDH Inhibitor Therapy in AML: Ivosidenib & Enasidenib Mono and C…

Feat. C. DiNardo
10:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Manipulating Microenvironment to Overcome Chemotherapy Resistance in…

Feat. D. DeAngelo
22:31
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Identification and Management of Patients with Polycythemia Vera and…

Feat. S. Verstovsek
15:43
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Combination Approaches With Ruxolitinib in Primary Myelofibrosis - W…

Feat. N. Pemmaraju
13:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Identification and Management of Ruxolitinib Failure in Myelofibrosi…

Feat. L. Masarova
10:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treat…

Feat. K. Dunleavy
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from th…

Feat. A. Zelenetz
11:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin…

Feat. A. Moskowitz
31:49
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

From CHIP, ICUS, and CCUS to Myelodysplastic Syndromes: Disease Stat…

Feat. L. Godley
20:22
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Lower Risk Myelodysplastic Syndromes Management: Overview of the Cur…

Feat. R. Komrokji
25:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Higher Risk Myelodysplastic Syndromes Management: Overview of the Cu…

Feat. V. Santini
09:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal an…

Feat. A. Krishnan
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/R…

Feat. M. Dimopoulos
17:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Epigenetic Mechanisms in CLL: Inter- and Intra-Patient Heterogeneity…

Feat. D. Rossi
19:03
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Mechanisms of Resistance in CLL to Targeted Agents: Could We Use The…

Feat. P. Ghia
18:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Genomic Complexity of CLL: Complex Karyotype, Cytogenetic Complexity…

Feat. R. Brandell